A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Active:	Yes
Cancer Type:	Gynecologic Cancers Ovarian Cancer Primary Peritoneal Cancer Unknown Primary	NCT ID:	NCT07213804
Trial Phases:	Phase III	Protocol IDs:	27727 (primary) NCI-2026-00146 2025-522255-25-00 APGOT-OV17 ENGOT-ov97/GINECO-NOGGO GOG-3133 J5E-MC-JZXB
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT07213804

Summary

This is a clinical study that has two parts. It is testing a potential new medicine
called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian,
peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no
longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at
participants whose cancer still responds to platinum-based treatments. The researchers
want to find out if Sofetabart Mipitecan works better than the usual treatments that
doctors use now and to better understand how safe it is. Each participant's time in the
study will depend on how they respond to the treatment.

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.